{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:47:55Z","timestamp":1781970475553,"version":"3.54.5"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["2R44 AI125060-02"],"award-info":[{"award-number":["2R44 AI125060-02"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R43AR073727"],"award-info":[{"award-number":["R43AR073727"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR43510"],"award-info":[{"award-number":["R01AR43510"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR063650"],"award-info":[{"award-number":["R01 AR063650"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR070984"],"award-info":[{"award-number":["R21AR070984"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR069789"],"award-info":[{"award-number":["R21AR069789"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG049994"],"award-info":[{"award-number":["R01AG049994"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG059775"],"award-info":[{"award-number":["R01AG059775"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R42-DE025789-02"],"award-info":[{"award-number":["R42-DE025789-02"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bone.2020.115492","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:32:24Z","timestamp":1592883144000},"page":"115492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Targeting anti-cancer agents to bone using bisphosphonates"],"prefix":"10.1016","volume":"138","author":[{"given":"Lianping","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert K.","family":"Boeckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkat","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi K.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan F.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bone.2020.115492_bb0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2020.115492_bb0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0015","first-page":"24","article-title":"Bone metastasis: concise overview","volume":"32","author":"Chin","year":"2015","journal-title":"Fed. Pract."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007702","article-title":"Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval","volume":"5","author":"Cetin","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","article-title":"Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999\u20132006","volume":"131","author":"Sathiakumar","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.bone.2020.115492_bb0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00132-011-1866-7","article-title":"Primary malignant bone tumors","volume":"40","author":"von Eisenhart-Rothe","year":"2011","journal-title":"Orthopade"},{"key":"10.1016\/j.bone.2020.115492_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, chondrosarcoma, and Ewing\u2019s sarcoma: National Cancer Data Base Report","volume":"459","author":"Damron","year":"2007","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"9","key":"10.1016\/j.bone.2020.115492_bb0050","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/cncr.23866","article-title":"Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975\u20131999","volume":"113","author":"Linabery","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bone.2020.115492_bb0055","first-page":"705","article-title":"Osteosarcoma: a review of diagnosis, management, and treatment strategies","volume":"8","author":"Geller","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.bone.2020.115492_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4419-0284-9_2","article-title":"The etiology of osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat. Res."},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/RLU.0000000000001646","article-title":"68Ga-PSMA PET\/CT in osteosarcoma in fibrous dysplasia","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bone.2020.115492_bb0070","first-page":"64(10)","article-title":"Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000\u20132013","author":"Moreno","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.bone.2020.115492_bb0075","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bone.2020.115492_bb0085","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","author":"Thorsteinsdottir","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0090","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis","volume":"163","author":"Pozzi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.bone.2020.115492_bb0100","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bone.2020.115492_bb0105","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00774-008-0012-z","article-title":"Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production","volume":"27","author":"Abe","year":"2009","journal-title":"J. Bone Miner. Metab."},{"issue":"8","key":"10.1016\/j.bone.2020.115492_bb0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: the fatal interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2353\/ajpath.2007.061164","article-title":"Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy","volume":"171","author":"Bodo","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2020.115492_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"Bone Rep."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0135","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","article-title":"Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo","volume":"27","author":"Roelofs","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/ml5004603","article-title":"Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters","volume":"6","author":"Puljula","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bone.2020.115492_bb0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2018.03.010","article-title":"Targeting therapeutics to bone by conjugation with bisphosphonates","volume":"40","author":"Young","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.bone.2020.115492_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","article-title":"Targeted delivery to bone and mineral deposits using bisphosphonate ligands","volume":"99","author":"Cole","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bone.2020.115492_bb0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1039\/B512310K","article-title":"\u2018Magic bullets\u2019 for bone diseases: progress in rational design of bone-seeking medicinal agents","volume":"36","author":"Zhang","year":"2007","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.bone.2020.115492_bb0160","first-page":"729","article-title":"Novel bone-targeted Src tyrosine kinase inhibitor drug discovery","volume":"6","author":"Shakespeare","year":"2003","journal-title":"Curr. Opin. Drug Discov .Devel."},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1747-0285.2007.00615.x","article-title":"SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity","volume":"71","author":"Shakespeare","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"issue":"20 Pt 2","key":"10.1016\/j.bone.2020.115492_bb0170","doi-asserted-by":"crossref","first-page":"6291s","DOI":"10.1158\/1078-0432.CCR-06-0991","article-title":"SRC inhibitors in metastatic bone disease","volume":"12","author":"Boyce","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"49","key":"10.1016\/j.bone.2020.115492_bb0175","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0180","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"Boyce","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bone.2020.115492_bb0185","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0190","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bone.2020.115492_bb0195","series-title":"Bisphosphonate Therapy in Acute and Chronic Bone Loss: Physical Chemical Considerations in Bisphosphonate-Related Therapies","first-page":"125","article-title":"Chapter 8","author":"Ebrahimpour","year":"1995"},{"key":"10.1016\/j.bone.2020.115492_bb0200","unstructured":"Sunberg, R.J.E., F.H., Mosher, C.T., Roof, C., Designing drugs for stronger bones. Chemtech, 1991. 21: p. 304\u2013309."},{"issue":"23","key":"10.1016\/j.bone.2020.115492_bb0205","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bone.2020.115492_bb0210","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","article-title":"Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis","volume":"7","author":"Gil","year":"1999","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bone.2020.115492_bb0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.2018-0707","article-title":"First-in-human phase I study of MBC-11, a novel bone-targeted cytarabine-etidronate conjugate in patients with cancer-induced bone disease","volume":"24","author":"Zinnen","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0220","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","article-title":"Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis","volume":"20","author":"Arns","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bone.2020.115492_bb0225","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bmc.2009.12.041","article-title":"Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens","volume":"18","author":"Morioka","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0230","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acs.jmedchem.6b01615","article-title":"Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms","volume":"60","author":"Sedghizadeh","year":"2017","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bone.2020.115492_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10237","article-title":"In vivo bone effects of a novel bisphosphonate-EP4a conjugate drug (C3) for reversing osteoporotic bone loss in an ovariectomized rat model","volume":"3","author":"Sheikh","year":"2019","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0240","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jbmr.2382","article-title":"Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss","volume":"30","author":"Liu","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0245","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bmcl.2010.01.006","article-title":"Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis","volume":"20","author":"Tanaka","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bone.2020.115492_bb0250","doi-asserted-by":"crossref","first-page":"115394","DOI":"10.1016\/j.bone.2020.115394","article-title":"Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance","volume":"137","author":"Sfeir","year":"2020","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-015-0748-x","article-title":"Duration of anti-resorptive therapy for osteoporosis","volume":"51","author":"Adler","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115492_bb0265","article-title":"Targeted delivery to bone and mineral deposits using bisphosphonate ligands","author":"Cole","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bone.2020.115492_bb0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.021","article-title":"Impact of chemotherapy on gastrointestinal functions and the enteric nervous system","volume":"105","author":"Escalante","year":"2017","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/jbiol73","article-title":"How chemotherapy damages the central nervous system","volume":"7","author":"Meyers","year":"2008","journal-title":"J. Biol."},{"issue":"3","key":"10.1016\/j.bone.2020.115492_bb0280","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3892\/ijo_00000705","article-title":"Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis","volume":"37","author":"Holmberg","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2020.115492_bb0285","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.21873\/anticanres.11249","article-title":"Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer: a multicenter phase 1 study","volume":"36","author":"Thellenberg-Karlsson","year":"2016","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11914-007-0012-2","article-title":"Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today?","volume":"5","author":"Ioachimescu","year":"2007","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2020.115492_bb0295","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.bone.2010.10.145","article-title":"Evaluation of a novel bone targeted aracytidine therapy in dogs with spontaneous osteosarcoma","volume":"48","author":"Zinnen","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0300","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acs.bioconjchem.9b00210","article-title":"12b80 - Hydroxybisphosphonate linked doxorubicin: bone targeted strategy for treatment of osteosarcoma","volume":"30","author":"David","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.bone.2020.115492_bb0305","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1021\/acsami.8b18820","article-title":"Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of Orthotopic osteosarcoma","volume":"11","author":"Feng","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0310","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/s41598-020-62039-2","article-title":"Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity","volume":"10","author":"Nadar","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R D"},{"issue":"11","key":"10.1016\/j.bone.2020.115492_bb0320","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0325","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","article-title":"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma","volume":"21","author":"Bonvini","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bone.2020.115492_bb0330","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0335","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bone.2020.115492_bb0340","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3816\/CLM.2007.n.045","article-title":"Bortezomib inhibits osteoclast activity in patients with multiple myeloma","volume":"7","author":"Uy","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.bone.2020.115492_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.294","article-title":"Withaferin a: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone","volume":"4","author":"Khedgikar","year":"2013","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0350","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115492_bb0355","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.bone.2020.115492_bb0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.bone.2020.115492_bb0365","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"38","key":"10.1016\/j.bone.2020.115492_bb0370","doi-asserted-by":"crossref","first-page":"18387","DOI":"10.1039\/C8NR03899F","article-title":"Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy","volume":"10","author":"Zhu","year":"2018","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.bone.2020.115492_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030154","article-title":"Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice","volume":"10","author":"Wang","year":"2018","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010083","article-title":"Anabolic Therapies in Osteoporosis and Bone Regeneration","volume":"20","author":"Russow","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41584-019-0172-3","article-title":"Antiresorptive and anabolic agents in the prevention and reversal of bone fragility","volume":"15","author":"Seeman","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.bone.2020.115492_bb0390","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.bone.2020.115492_bb0395","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2146\/ajhp130281","article-title":"Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma","volume":"72","author":"McBride","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bone.2020.115492_bb0400","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"10.1016\/j.bone.2020.115492_bb0405","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0410","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1172\/JCI66947","article-title":"Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation","volume":"124","author":"Xiu","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bone.2020.115492_bb0415","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41467-019-10677-0","article-title":"TGFbeta-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2020.115492_bb0420","unstructured":"Yao, Z., Hou, X., Lei, W., Xiao, L., Ebetino, FH., Boechman, RK., Boyce, B., Bone Targeted Chloroquine Inhibits Osteoclastogenesis and Bone Resorption More Effectively than Chloroquine. ASBMR 2016 Annual Meeting, 2016. (No. SU0161)."},{"issue":"8","key":"10.1016\/j.bone.2020.115492_bb0425","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.2012.064923","article-title":"DangER: protein ovERload. Targeting protein degradation to treat myeloma","volume":"97","author":"Aronson","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bone.2020.115492_bb0430","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","article-title":"Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation","volume":"68","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2020.115492_bb0435","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1182\/blood.V124.21.5775.5775","article-title":"A phase II trial of chloroquine in combination with bortezomib and cyclophosphamide in patients with relapsed and refractory multiple myeloma","volume":"124","author":"Montanari","year":"2014","journal-title":"Blood"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:40:45Z","timestamp":1762659645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220302726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":87,"alternative-id":["S8756328220302726"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115492","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting anti-cancer agents to bone using bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115492"}}